AC Immune (ACIU) said Wednesday that the US Food and Drug Administration has issued a Fast Track Designation for the PI-2620 Tau positron emission tomography, or PET, imaging agent that the company is developing with privately held Life Molecular Imaging to diagnose three neurodegenerative conditions, including Alzheimer's disease.
The Fast Track Designation also covers PI-2620 as a potential diagnostic for progressive supranuclear palsy and corticobasal degeneration, AC Immune said.
PI-2620 is in phase 3 clinical development for detecting Tau pathology in Alzheimer's disease and could eventually be adapted also for non-Alzheimer tauopathies such as progressive supranuclear palsy and corticobasal syndrome, the company said.
AC Immune rose nearly 2% in early trading Wednesday.
Price: 3.1200, Change: +0.06, Percent Change: +1.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。